A Comparative Randomized Prospective Study to Evaluate Efficacy and Safety of Combination of Tamsulosin and Tadalafil vs. Tamsulosin or Tadalafil Alone in Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia

被引:64
|
作者
Singh, Dig Vijay [1 ]
Mete, Uttam Kumar [1 ]
Mandal, Arup Kumar [1 ]
Singh, Shrawan Kumar [1 ]
机构
[1] Post Grad Inst Med Educ & Res, Dept Urol, Chandigarh 160012, India
来源
JOURNAL OF SEXUAL MEDICINE | 2014年 / 11卷 / 01期
关键词
Tamsulosin; Tadalafil; Benign Prostatic Hyperplasia; Lower Urinary Tract Symptoms; Erectile Dysfunction; Medical Therapy; COMBINED ORAL-THERAPY; ERECTILE DYSFUNCTION; PHOSPHODIESTERASE-5; INHIBITORS; INTEGRATED APPROACH; SILDENAFIL CITRATE; SEXUAL DYSFUNCTION; ALPHA-BLOCKERS; MEN; EPIDEMIOLOGY; ALFUZOSIN;
D O I
10.1111/jsm.12357
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and erectile dysfunction are common disorders of advancing age. Aim To evaluate the efficacy and safety of tamsulosin and tadalafil in patients with LUTS due to BPH. Methods In this prospective randomized study, 133 men complaining of LUTS due to BPH were included. Forty-five patients received tamsulosin 0.4 mg/day alone (Group A), 44 patients received tadalafil 10 mg/day (Group B), and combination therapy (tamsulosin and tadalafil both) was instituted in 44 patients (Group C). After a 2-week medication free run-in period, they were evaluated for International Prostatic Symptom Score (IPSS), International Index of Erectile Function score (IIEF5), quality of life (IPSS QoL), maximum urinary flow rate (Qmax), post-void residual urine (PVR) volume, and safety parameters before and at 3 months of treatment. Main Outcome Measures There were primary (IPSS, IPSS QoL index, Qmax, and PVR) and secondary (erectile function [EF] domain scores from IIEF5) efficacy end points. Safety assessment included laboratory tests and patient's reporting of adverse event. Results A significant improvement in IPSS score was observed in all the 3 groups A, B, and C (-50.90%, P<0.05; -33.50%, P<0.05; and -53.90%, P<0.05, respectively). IIEF5 score increased significantly in these three groups (+39.28%, P<0.05; +45.96%, P<0.05; and +60.23%, P<0.05, respectively). A significant increase in Qmax and decrease in PVR were also observed (33.99%, P<0.05; 29.78%, P<0.05; and 37.04%, P<0.05) and (-60.90%, P<0.05; -49.45%, P<0.05; and -62.97%, P<0.05, respectively). The QoL scores improved significantly (-73.35%, P<0.05; -70.26%, P<0.05; and -79.65%, P<0.05, respectively). Side effects were dyspepsia, heartburn, headache, flushing, myalgia, and backache. Adverse effect dropout was 3.7%. No participant experienced any severe or serious adverse events. Conclusions In patients with LUTS due to BPH, tamsulosin and tadalafil alone or in combination cause a significant improvement in patients with LUTS. Their EF also improves with these medications. The improvement is better with combination therapy compared with single agent alone.
引用
收藏
页码:187 / 196
页数:10
相关论文
共 50 条
  • [21] Tadalafil for the Treatment of Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia
    Rohrbough, C. R.
    Colgan, Bridget
    Gasser, Ollie
    AMERICAN FAMILY PHYSICIAN, 2024, 109 (01) : 83 - 84
  • [22] Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia
    McVary, Kevin T.
    Roehrborn, Claus G.
    Kaminetsky, Jed C.
    Auerbach, Stephen M.
    Wachs, Barton
    Young, Jay M.
    Esler, Anne
    Sides, Gregory D.
    Denes, Bela S.
    JOURNAL OF UROLOGY, 2007, 177 (04): : 1401 - 1407
  • [23] Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia
    Kose, Gokhan
    Tekin, Ilteris
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2007, 6 (01): : 34 - 36
  • [24] Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
    Gonzalez, Ricardo R.
    Kaplan, Steven A.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2006, 2 (04) : 609 - 617
  • [25] Comparing Monotherapy with Tadalafil or Tamsulosin and Their Combination Therapy in Men with Benign Prostatic Hyperplasia: A Randomized Clinical Trial
    Karami, Hossein
    Hassanzadeh-Hadad, Amin
    Fallah-Karkan, Morteza
    UROLOGY JOURNAL, 2016, 13 (06) : 2920 - 2926
  • [26] A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
    Rigatti, P
    Brausi, M
    Scarpa, RM
    Porru, D
    Schumacher, H
    Rizzi, CA
    PROSTATE CANCER AND PROSTATIC DISEASES, 2003, 6 (04) : 315 - 323
  • [27] Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia
    Daisuke Gotoh
    Kazumasa Torimoto
    Yosuke Morizawa
    Shunta Hori
    Yasushi Nakai
    Makito Miyake
    Kiyohide Fujimoto
    BMC Research Notes, 15
  • [28] A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
    P Rigatti
    M Brausi
    R M Scarpa
    D Porru
    H Schumacher
    C A Rizzi
    Prostate Cancer and Prostatic Diseases, 2003, 6 : 315 - 323
  • [29] Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia
    Gotoh, Daisuke
    Torimoto, Kazumasa
    Morizawa, Yosuke
    Hori, Shunta
    Nakai, Yasushi
    Miyake, Makito
    Fujimoto, Kiyohide
    BMC RESEARCH NOTES, 2022, 15 (01)
  • [30] Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia
    Narayan, P
    Evans, CP
    Moon, T
    JOURNAL OF UROLOGY, 2003, 170 (02): : 498 - 502